BioCryst制药

BCRX NASDAQ
2.500
-0.070
-2.72%
盘后: 2.500 0 0.00% 16:00 08/23 EDT
开盘
2.560
昨收
2.570
最高
2.680
最低
2.490
成交量
132.68万
成交均量(3M)
180.22万
52周最高
9.95
52周最低
2.490
换手率
1.20%
市值
2.76亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供BioCryst制药 BCRX股票价格,BioCryst制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
展开 >

最近浏览

名称
价格
涨跌幅